comparemela.com

Latest Breaking News On - Mucocutaneous reactions - Page 1 : comparemela.com

FDA Approves Amgen s RIABNI(TM) (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)

Search jobs FDA Approves Amgen s RIABNI(TM) (rituximab-arrx), A Biosimilar To Rituxan® (rituximab) THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® (rituximab), for the treatment of adult patients with Non-Hodgkin s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021. The approval of RIABNI represents an important milestone across our biosimilar and oncology portfolios, said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. Following the proven success of KANJINTI

Puerto ricoTrish rowlandHypogammaglobulinemia igAmgen biosimilarsKelley davenportMurdo gordonExchange commissionPfizer incEuropean unionDrug administrationBeigene ltdCelltrion incChronic lymphocytic leukemiaMicroscopic polyangiitisGlobal commercial operationsWholesale acquisition cost

FDA Approves Amgen s RIABNI , A Biosimilar To Rituxan®

Amgen today announced that the U.S. Food and Drug Administration has approved RIABNI™ a biosimilar to Rituxan ® for the treatment of adult patients with Non-Hodgkin’s Lymphoma Chronic Lymphocytic Leukemia Granulomatosis with Polyangiitis and Microscopic Polyangiitis . RIABNI will be made available in the U.S. in January 2021 . “The approval of RIABNI represents an important milestone across our biosimilar and … Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021 .

Puerto ricoTrish rowlandHypogammaglobulinemia igAmgen biosimilarsKelley davenportMurdo gordonExchange commissionPfizer incEuropean unionDrug administrationBeigene ltdCelltrion incChronic lymphocytic leukemiaMicroscopic polyangiitisGlobal commercial operationsWholesale acquisition cost

FDA Approves Amgen s RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)

Share this article Share this article THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® (rituximab), for the treatment of adult patients with Non-Hodgkin s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021. The approval of RIABNI represents an important milestone across our biosimilar and oncology portfolios, said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. Following the proven success of KANJINTI

Puerto ricoTrish rowlandHypogammaglobulinemia igAmgen biosimilarsKelley davenportMurdo gordonExchange commissionPfizer incEuropean unionDrug administrationBeigene ltdCelltrion incChronic lymphocytic leukemiaMicroscopic polyangiitisGlobal commercial operationsWholesale acquisition cost

vimarsana © 2020. All Rights Reserved.